吴魁
博士/副教授/硕士生导师
武汉科技大学 化学与化工学院
Email：wukui@wust.edu.cn


教育&工作背景
2001-2005 武汉理工大学-工学学士
2005-2007 华中科技大学-理学硕士
2007-2011 中国科学院化学研究所-理学博士
2011-2014 中国科学院化学研究所-博士后
2014-2017 中国科学院化学研究所-助理研究员
2018-至今 武汉科技大学 化学与化工学院-副教授

研究方向和兴趣
主要从事生物无机化学、化学生物学及分析化学相关研究工作：
1. 金属抗肿瘤药物与生物靶分子的相互作用
2. 新型金属抗肿瘤药物的设计与合成
3. 质谱成像、质谱分析、核磁共振波谱分析等

社会兼职
中国化学会会员
Dalton Trans. J. Am. Soc. Mass Spectrom.、J. Inorg. Biochem.等SCI 期刊审稿人

奖励与荣誉
2014，中国分析测试协会科学技术奖二等奖
2018，湖北省“楚天学者计划”（楚天学子）

讲授课程
《绿色化学》 本科生
《制药工程导论》 本科生

主持或参与科研项目
1. 湖北省人才项目：湖北省“楚天学者计划”（楚天学子）（2018.01-2020.12）主持
2. 国家自然科学基金委青年基金项目：基于二次离子质谱成像的金属抗癌药物对微量元素胞内平衡的干扰研究（2016.1- 2018.12）主持
3. 国家自然科学基金委重点项目： 基于 Cell-SELEX 的生物标志物发现方法学研究
（2017.1-2021.12）参加
4. 国家自然科学基金委青年基金项目：基于质谱的金属抗肿瘤药物细胞蛋白质组学研究
（2017.1-2019.12）参加
5. 国家自然科学基金委联合重大研究计划培育项目：应用二次离子质谱成像技术研究大气细颗粒物的结构和毒性组分的形成和来源（2016.1-2018.12）参加
6. 国家自然科学基金委青年基金项目：光活性多靶点铂基抗癌药物的设计合成和构效关系研究（2014.1-2016.12）参加
7. 国家自然科学基金委面上项目：微纳米DNA 探针捕获蛋白质-质谱分析联用研究肿瘤细胞对金属抗肿瘤药物的应答机制（2013.1-2016.12）参加
8. 国家自然科学基金重点项目：调控蛋白与药物损伤 DNA 相互作用研究的分析新方法（2012.1
- 2016.12）参加
9. 国家自然科学基金委面上项目：LC-MS 研究金属抗肿瘤药物与血清蛋白的相互作用（2010.1
- 2012.12）参加

发表论文
2021 年
[1] Y. Lin,? K. Wu,? F. F. Jia,?( ? co-first author) L. Chen, Z. Y. Wang, Y. Y. Zhang, Q. Luo, S.
Y. Liu, L. Y. Qi, N. Li, P. Dong, F. Gao, W. Zheng, X.. H. Fang,* Y. Zhao*, F. Y. Wang*, Single
cell imaging reveals cisplatin regulating interactions between transcription (co)factors
and DNA, Chem. Sci., 2021, DOI: 10.1039/d0sc06760a.
[2] 2020 年
[3] Y. Y. Cheng?, J. S. Zhang?, K. Wu*, F. Gao, Y. Cheng, T. Zou, X. Q. Wu, Y. Zhao*, F.Y. Wang,
Photoactivatable diazido Pt(IV) anticancer complex can bind to and oxidize all four nucleosides,
Dalton Trans., 2020, 49, 17157-17163.
[4] C. Huang, Z. Q. Ma, J. F. Lin, X. X. Gong, F. F. Zhang, X. Q. Wu*, F. Y. Wang, W. Zheng, Y.
Zhao*, K. Wu*, Tandem Mass Spectrometry Reveals Preferential Ruthenation of Thymines in Human
Telomeric G-quadruplex DNA by an Organometallic Ruthenium Anticancer Complex,
Organometallics, 2020, 39, 3315-3322.
[5] Z. J. Liang, J. F. Lin, X. X. Gong, Y. Y. Cheng, C. Huang, J. S. Zhang, X. Q. Wu, F. Y. Wang,
Y. Zhao*, K. Wu*, Reactions of a photoactivatable diazido Pt(IV) anticancer complex with
a single-stranded oligodeoxynucleotide, Dalton Trans., 2020, 49, 11249-11259.
[6] J. S. Zhang?, W. J. Zeng?, K. Wu*, J. Ye, Y. Y. Cheng, Y. Cheng, T. Zou, N. Peng, X. Q. Wu,
Y. Zhao*, F. Y. Wang*, Unexpected thymine oxidation and collision-induced thymine-Pt-guanine

crosslinking on 5 ? -TpG and 5 ? -GpT by a photoactivatable diazido Pt(IV) anticancer
complex,
Inorg. Chem., 2020, 59, 8468-8480.
[7] C. Y. Li, F. M. Xu, Y. Zhao, W. Zheng, W. J. Zeng, Q. Luo, Z. Y. Wang, K. Wu, J. Du, F.
Y. Wang*, Platinum(II) Terpyridine Anticancer Complexes Possessing Multiple Mode of DNA
Interaction and EGFR Inhibiting Activity, Front. Chem, 2020, 8, 210.
[8] Y. Zhao, H. Y. Huang, Y. Y. Zhang, K. Wu, F. G. Zeng, J. G. Wang, X. F. Yu, Z. H. Zhu, X.-Y.
Yu, F. Y. Wang*, Atmospheric particulate characterization by ToF-SIMS in an urban site
in Beijing, Atmos. Environ., 2020, 220, 117090.
[9] F. F. Jia, K. Wu, Y. L. Che, Y. Y. Zhang, F. G. Zeng, Q. Luo, X.-Y. Yu, Z. H. Zhu, Y. Zhao*,
F. Y. Wang*, ToF-SIMS analysis of chemical composition of atmospheric aerosols in Beijing,
Surf. Interface Anal., 2020, 52, 272-282.
[10] Y. Cheng, R. Q. Song, K. Wu, N. Peng, M. Yang, J. Luo, T. Zou*, Y. G. Zuo*, Y. Liu*,
The enhanced visible-light-driven antibacterial performances of
PTCDI-PANI(Fe(III)-doped) heterostructure, J. Hazard. Mater., 2020, 383: 121166.
[11] Y. Cheng*, Z. S. Zhao, K. Wu, T. Zou, C. Wang, Q. Zheng, W. J. Song*, Reversal
of the photoinduced majority carriers in polypyrrole by
semiconductor-insulator-semiconductor heterostructure and related highly efficient photoreduction
of Cr(VI), Chem. Eng. J., 2020, 393, 124720.
2019 年
[1] W. J. Zeng, Y. Y. Zhang, W. Zheng, Q. Luo, J. J. Han, J. A. Liu, Y. Zhao, F. F. Jia, K. Wu*,
F. Y. Wang*, Discovery of Cisplatin Binding to Thymine and Cytosine on a
Single-Stranded Oligodeoxynucleotide by High Resolution FT-ICR Mass Spectrometry, Molecules,
2019, 24, 1852.
[2] W. J. Zeng, Z. F. Du, Q. Luo, Y. Zhao, Y. Y. Wang, K. Wu, F. F. Jia, Y. Y. Zhang* and Fuyi
Wang*, Proteomic Strategy for Identification of Proteins Responding to Cisplatin-Damaged DNA, Anal.
Chem., 2019, 91: 6035–6042.
[3] Y. Lin, J. Wang, W. Zheng, Q. Luo, K. Wu, J. Du, Y. Zhao, F. Y. Wang*,
Organometallic ruthenium anticancer complexes inhibit human peroxiredoxin I activity by
binding to and inducing oxidation of its catalytic cysteine residue, Metallomics, 2019, 11,
546-555.
[4] Y. M. Han, W. Guo, W. Zheng, Q. Luo, K. Wu, Y. Zhao*, F. Y. Wang, Mass
Spectrometric Quantification for the Binding Ratio of Metal-Based Anticancer Complexes with Protein
Thiols, Rapid Commun. Mass Spectrom., 2019, 33, 951-958.
[5] S. L. Jia, R. J. Wang, K. Wu, H. L. Jiang, Z. F. Du,* Elucidation of the Mechanism of Action
for Metal Based Anticancer Drugs by Mass Spectrometry-Based Quantitative Proteomics, Molecules,
2019, 24, 581.
[6] N. Peng*, M. Y. Yang, Y. Tang, T. Zou, F. Guo, K. Wu, X. Q. Wang, X. F. Li,
Y. Liu*, Amphiphilic hexadecyl-quaternized chitin micelles for doxorubicin delivery,
Int. J. Biol. Macromol., 2019, 130: 615-621.
2018 年

[1] Y. Y. Cheng, W. J. Zeng, Y. Cheng, J, S. Zhang, T. Zou, K. Wu*, F. Y. Wang,* Selective
binding of an organoruthenium complex to G-rich human telomeric sequence by
tandem mass spectrometry, Rapid Commun. Mass Spectrom., 2018, 32: 2152-2158.
[2] S. Y. Liu, A. H. Liang, K. Wu*, W. J. Zeng, Q. Luo and F. Y. Wang,* Binding of Organometallic
Ruthenium Anticancer Complexes to DNA: Thermodynamic Base and Sequence Selectivity, Int.
J. Mol. Sci. 2018, 19, 2137
[3] C.-F. Shao, Y. Zhao, K. Wu, F. F. Jia, Q. Luo, Z. Liu, F. Y. Wang, Correlated Secondary Ion
Mass Spectrometry-Laser Scanning Confocal Microscopy Imaging for Single Cell-Principles and
Applications, Chin. J. Anal. Chem., 2018, 46, 1005-1016.
2017 年
[1] S. Y. Liu, W. Zheng, K. Wu*, F. F. Jia, Z. Y. Wang, Q. Luo, Y. Zhao, Y. Zhang, F. Y.
Wang,* Correlated Mass Spectrometry Imaging and Fluorescence Imaging Reveals Dual-Targeting
Action of an Organometallic Ruthenium Anticancer Complex, Chem. Commun., 2017, 53,
4136-4139.
[2] K. Wu?, F. F. Jia?, Q. Luo, Y. Zhao, F. Y. Wang,* Mass spectrometric imaging of metallodrugs
in single cells by secondary ion mass spectrometry, J. Biol. Inorg. Chem., 2017, 22, 653-661.
[3] 吴魁，罗群，赵耀，郑伟，汪福意*，质谱在金属抗肿瘤化合物分子作用机理研究中的应用，
中国科学:化学，2017, 47, 233-248。
[4] Z. Y. Wang, Y. Y. Zhang, B. W. Liu, K. Wu, S. Thevuthasan, D. Baer, Z. H. Zhu,* X. Y. Yu,* F.
Y. Wang,* In situ Mass Spectrometric Monitoring of the Dynamic Electrochemical Process at the
Electrode-Electrolyte Interface: a SIMS Approach, Anal. Chem., 2017, 89, 960-965.
[5] W. Zheng, Y. Zhao, Q. Luo, Y. Zhang, K. Wu, F. Y. Wang, Multi-Targeted Anticancer Agents,
Curr. Topics Med. Chem., 2017, 17, 3084-3098.
[6] Y. Y. Wang, Z. F. Du,* W. Zheng, K. Wu, D. C. Xu, Q. Luo, Y. Zhao, J. J. Han, Y. Z. Liu, F.
Y. Wang,* Deciphering of Interactions between Platinated DNA and
HMGB1 by Hydrogen/Deuterium Exchange Mass Spectrometry, Dalton Trans., 2017, 46, 6187-6195.
[7] G. Z. Zhai, X. Y. Wu, K. Wu, Q. Luo, Y. Zhao, J. A. Liu, S. X. Xiong, Y. Q. Feng, L. P.
Yang,* F.
Y. Wang*, Evaluation of serum phosphopeptides as potential biomarkers of gastric cancer, RSC
Advances, 2017, 7, 21630-21637.
[8] Y. L. Jin, Y. F. Xie, K. Wu, Y. Y. Huang,* F. Y. Wang,* R. Zhao,* Probing
the dynamic interaction between damaged DNA and a cellular responsive protein using a
piezoelectric mass biosensor, ACS Appl. Mater. Interfaces, 2017, 9, 8490-8497.
2016 年及以前
[1] L. J. Li, W. Guo, K. Wu*, Y. Zhao, Q. Luo, Q. W. Zhang,* J. A. Liu, S. X. Xiong, F. Y.
Wang, Identification of Binding Sites of Cisplatin to Human Copper Chaperone Protein Cox17 by High
Resolution FT-ICR-MS, Rapid Commun. Mass Spectrom., 2016, 30, 168-172.
[2] L. J. Li, W. Guo, K. Wu*, X. L. Wu, L. H. Zhao, Y. Zhao, Q. Luo, Y. Y. Wang, Y. Z. Liu, Q. W.
Zhang, F. Y. Wang,* A Comparative Study on the Interactions of Human Copper Chaperone
Cox17 with Anticancer Organoruthenium(II) Complexes and Cisplatin by Mass Spectrometry, J.

Inorg. Biochem., 2016, 161, 99-106.
[3] 翟贵金，吴魁，汪福意*，血清磷酸化肽的分离富集和质谱定量及其作为潜在肿瘤标志物的评价，色谱，2016，34，1192-1198.
[4] J. Du, Y. Kang, Y. Zhao,* W. Zheng, Y. Zhang, Y. Lin, Z. Y. Wang, Y. Y. Wang, Q. Luo, K. Wu,
F.
Y. Wang,* Synthesis, Characterization, and in Vitro Antitumor Activity of Ruthenium(II)
Polypyridyl Complexes Tethering EGFR-Inhibiting 4-Anilinoquinazolines, Inorg. Chem., 2016, 55,
4595-4605.
[5] Y. Lin, Y. D. Huang, W. Zheng, K. Wu, Q. Luo, Y. Zhao, S. X. Xiong, F. Y.
Wang,* Quantification of bindings of organometallic ruthenium complexes to GSTπ
by mass spectrometry, J. Inorg. Biochem. 2015, 146, 44-51.
[6] J. Du, E. L. Zhang, Y. Zhao,* W. Zheng, Y. Zhang, Y. Lin, Z. Y. Wang, Q. Luo, K. Wu, F. Y.
Wang,* Discovery of a dual-targeting organometallic ruthenium complex with high activity
inducing early stage apoptosis of cancer cells, Metallomics, 2015, 7, 1573-1583.
[7] G. J. Zhai, X. Y. Wu, Q. Luo, K. Wu, Y. Zhao, J. A. Liu, S. X. Xiong, Y. -Q. Feng, L. P.
Yang, F. Y. Wang,* Evaluation of serum phosphopeptides as potential cancer
biomarkers by mass spectrometric absolute quantification, Talanta 2014, 125, 411-417.
[8] S. Y. Liu, K. Wu*, W. Zheng, Q. Luo, Y. Zhao, F. Y. Wang,* Identification and discrimination
of binding sites of an organoruthenium anticancer complex to single-stranded oligonucleotides by
mass spectrometry, Analyst 2014, 139, 4491-4496.
[9] Z. Du, Q. Luo, L. Yang, T. Bing, X. Li, W. Guo, K. Wu, Y. Zhao, S. Xiong, D. Shangguan, F. Y.
Wang,* Mass Spectrometric Proteomics Reveals that Nuclear Protein Positive Cofactor PC4
Selectively Binds to Cross-Linked DNA by a trans-Platinum Anticancer Complex, J. Am. Chem. Soc.
2014, 136, 2948-2951.
[10] K. Wu?, S. Y. Liu?, Q. Luo, W. B. Hu, X. C. Li, F. Y. Wang,* R. H. Zheng, J. Cui, P. J.
Sadler,* J.
F. Xiang, Q. Shi, S. X. Xiong. Thymines in Single Stranded Oligonucleotides and G-quadruplex DNA
are Competitive with Guanines for Binding to an Organoruthenium Anticancer Complex, Inorg. Chem.
2013, 52, 11332-11342.
[11] K. Wu, W. B. Hu, Q. Luo, X. C. Li, S. X. Xiong, P. J. Sadler, F. Y. Wang,* Competitive Binding
Sites of a Ruthenium Arene Anticancer Complex on Oligonucleotides Studied by
Mass Spectrometry: Ladder-sequencing vs Top-down, J. Am. Soc. Mass Spectrom. 2013, 24, 410-420.
[12] F. Y. Wang, J. J. Xu, K. Wu, S. K. Weidt, C. L. Mackay, P. R. R. Langridge-Smith, P. J.
Sadler,* Competition between Glutathione and DNA Oligonucleotides for Ruthenium(II)
Arene Anticancer Complexes. Dalton Trans. 2013, 42, 3188-3195.
[13] K. Wu, Q. Luo, W. B. Hu, X. C. Li, F. Y. Wang,* S. X. Xiong, P. J. Sadler,*
Mechanism of Interstrand Migration of Organoruthenium Anticancer Complexes within a
DNA Duplex, Metallomics 2012, 4, 136-148.
[14] W. B. Hu, Q. Luo, K. Wu, X. C. Li, F. Y. Wang,* Y. Chen, X. Y. Ma, J. P. Wang, J. A. Liu, S.
X. Xiong, P. J. Sadler,* The Anticancer Drug Cisplatin can Cross-link the Interdomain Zinc Site on
Human Albumin, Chem. Commun. 2011, 47, 6006-6008.

[15] W. B. Hu, Q. Luo, X. Y. Ma, K. Wu, J. A. Liu, Y. Chen, S. X. Xiong, J. P. Wang, P. J. Sadler,
F. Y. Wang,* Arene Control over Thiolate to Sulfinate Oxidation in Albumin by
Organometallic Ruthenium Anticancer Complexes, Chem. Eur. J. 2009, 15, 6586-6594.